hrp0082p2-d3-556 | Puberty and Neuroendocrinology (2) | ESPE2014

Long Term Outcomes of Precocious Puberty due to Hypothalamic Hamartomas

Rodrigue Danielle , Thomas-Teinturier Cecile , Motte-Signoret Emmanuelle , Bougneres Pierre , Linglart Agnes

Background: Hypothamamic hamartomas (HH) are rare benign tumours of the tuber cinereum revealed by central precocious puberty (CPP) and, in some cases, gelastic seizures and cognitive impairment.Objective and hypotheses: Evaluation of the treament by GnRH analogues on control of puberty and final height in patients with HH.Method: We report a series of five cases of CPP secondary to HH (four girls and one boy). Early in infancy (9 ...

hrp0084p2-228 | Bone | ESPE2015

Online Survey to Characterise the Burden of Illness in Children with X-Linked Hypophosphatemia

Linglart Agnes , Dvorak-Ewell Melita , Marshall Ayla , Martin Javier San , Skrinar Alison

Background: X-linked Hypophosphatemia (XLH), the most common heritable form of rickets, is a disorder of renal phosphate wasting caused by high circulating levels of fibroblast growth factor 23 (FGF23) that impairs normal phosphate reabsorption in the kidney and production of the active form of vitamin D. Affected children present with hypophosphatemia resulting in rickets, bowing of the legs and short stature. Limited information is available about the disease burden in child...

hrp0094fc3.1 | Growth Disorders | ESPE2021

iPPSD: focus on neonatal features, preliminary data from a retrospective analysis of a large cohort of patients.

Del Sindaco Giulia , Pagnano Angela , Berkenou Jugurtha , Rothenbuhler Anya , Arosio Maura , Mantovani Giovanna , Linglart Agnes ,

Since the first description of pseudohypoparathyroidism (PHP), a remarkable clinical variability, which translates in several PHP subtypes, was observed. In 2016 a new classification of this group of diseases have been published by the European Network on PHP and related disorders, proposing “inactivating PTH/PTHrP signaling disorder” (iPPSD) as a new term that encompasses all the clinical entities, stressing the common mechanism responsible for all diseases. iPPSDs ...

hrp0094p1-95 | Thyroid A | ESPE2021

Prevalence and Characteristics of thyroid nodules in a pediatric population with congenital hypothyroidism

Ferri Marion , Rodrigue Danielle , Francois Papon Jean , Teinturier Cecile , Linglart Agnes , Sophie Lambert Anne ,

Objective: To assess the characteristics of thyroid nodules among infants diagnosed with congenital hypothyroidism and to discuss the interest of a systematic screening.Material and method: A retrospective study of children with congenital hypothyroidism due to dyshormonogenesis was carried out at the pediatric endocrine center in Kremlin Bicêtre hospital, Paris, between 1999 to 2020. A screening ultrasound for thyroid nodules was t...

hrp0094p2-304 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Impact of estrogen therapy on pubertal growth in Turner syndrome

Trouvin Marie-Agathe , Thomas-Teinturier Cecile , Bouvattier Claire , Duranteau Lise , Linglart Agnes ,

Short stature and hypogonadism are frequent symptoms in Turner syndrome (TS). In most cases, puberty must be induced but pubertal induction modalities are not consensual. Moreover, pubertal induction impact on final height and pubertal growth spurt has not been studied in depth. Our aim was to study factors influencing final height during pubertal induction in TS. Retrospective cohort of 45 TS girls followed in a single center: Bicetre hospital. We recorded auxological paramet...

hrp0097fc2.3 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Hyperparathyroidism after three years of burosumab in children affected with x-linked hypophosphatemia

V Zhukouskaya Volha , Ertl Diana-Alexandra , Berkenou Jugurtha , Audrain Christelle , Bardet Claire , Rothenbuhler Anya , Linglart Agnes

Background/aim: Hyperparathyroidism (HPHT) is a common feature in patients with X-linked hypophosphatemia (XLH) especially when treated with vitamin D analogues and phosphate supplements. Although the exact mechanism is not clear, it is assumed that phosphate supplements taken chronically stimulate parathyroid hormone (PTH) secretion. We prospectively assessed the effect of a novel pathogenetic treatment anti-FGF23 (burosumab) on PTH levels in children with XL...

hrp0097p1-269 | Fat, Metabolism and Obesity | ESPE2023

Impact of bariatric surgery on obesity complications in children and adolescents: Evaluation of a large cohort within a specialized French obesity center

Mosser Camille , Dagher Ibrahim , De Filippo Gianpaolo , Thebaut Alice , Linglart Agnès , Lambert Anne-Sophie

Summary: Severe obesity with various complications is a growing public health problem in childhood. Due to the lack of available hygienic and dietary therapeutic solutions, bariatric surgery has become, in recent years, one of the only effective treatments for severe obesity to induce persistant weight loss and reduce complications.Material and method: We analyzed a cohort of 162 patients followed in the specialized obes...

hrp0097p1-459 | Fat, Metabolism and Obesity | ESPE2023

Digestive manifestations are frequent in iPPSD/Pseudohypoparathyroidism

Goy Berenice , Rothenbuhler Anya , Audrain Christelle , Berkenou Jugurtha , Linglart Agnes , Dubern Beatrice

Introduction: Pseudohypoparathyroidism (hereafter named iPPSD for inactivating PTH/PTHrP Disorder) is a rare disease characterized by hormonal resistance including PTH, subcutaneous ossifications, short stature, brachymetacarpy and early onset obesity. iPPSD type 2 and 3 are caused by genetic or epigenetic variations in the GNAS gene or its promoters. Although uncommon features have been identified such as severe asthma or sleep apnea, digestive manifestations...

hrp0092rfc2.2 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Does the Treatment with Recombinant Human Growth Hormone Improve Final Height in Patients Affected by X-Linked Hypophosphatemia?

André Julia , Zhukouskaya Volha V. , Rothenbuhler Anya , Lambert Anne-Sophie , Salles Jean-Pierre , Mignot Brigitte , Linglart Agnès

Background/Aim: 25 to 40% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, despite optimal conventional treatment (oral phosphate supplementation and active forms of vitamin D) with final height -2 SDS. Recombinant human growth hormone (rhGH) may be an adjuvant treatment of the growth retardation in these patients. Therefore, the main objective of this study was to describe how rhGH treatment improves final heigh...

hrp0086rfc2.4 | Bone & Mineral Metabolism | ESPE2016

Results of Orthopaedic Surgery in Children with X-Linked Hypophosphatemic Rickets (XLHR)

Gizard Aliette , Rothenbuhler Anya , Pejin Zagorka , Finidori Georges , Glorion Christophe , de Billy Benoit , Linglart Agnes , Wicart Philippe

Background: XLHR is due to mutations in the PHEX gene leading to unregulated production of FGF23, hence hypophosphatemia and decreased renal 1,25OH-vitamin D hydroxylation. Amongst other features, XLHR is characterized by leg bowing of variable severity. Phosphate supplements and oral 1,25OH-vitamin D, partially or, in some cases, fully restore the limb straightness. For severe or residual limb deformities, orthopaedic surgery may be recommended.Objectiv...